Literature DB >> 27501327

Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS).

Xiaohua Wu1, Dawei Dong2, Daqing Ma1.   

Abstract

BACKGROUND SARS is not only an acute disease, but also leads to long-term impaired lung diffusing capacity in some survivors. However, there is a paucity of data regarding long-term CT findings in survivors after SARS. The aim of this study was to assess the changes in lung function and lung thin-section computed tomography (CT) features in patients recovering from severe acute respiratory syndrome (SARS), especially the dynamic changes in ground-glass opacity (GGO). MATERIAL AND METHODS Clinical and radiological data from 11 patients with SARS were collected. The serial follow-up thin-section CTs were evaluated at 3, 6, and 84 months after SARS presentation. The distribution and predominant thin-section CT findings of lesions were evaluated. RESULTS The extent of the lesions on the CT scans of the 11 patients decreased at 6 and 84 months compared to 3 months. The number of segments involved on 84-month follow-up CTs was less than those at 6 months (P<0.05). The predominant thin-section CT manifestation at 84 months (intralobular and interlobular septal thickening) was different than that at 6 months, at which GGO was predominant. CONCLUSIONS During convalescence after SARS, GGO and intralobular and interlobular septal thickening were the main thin-section CT manifestation. Intralobular and interlobular septal thickening predominated over GGO at 84 months.

Entities:  

Mesh:

Year:  2016        PMID: 27501327      PMCID: PMC4982531          DOI: 10.12659/msm.896985

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Severe acute respiratory syndrome (SARS) is an emergent infectious disease that was epidemic in 2002 and 2003 [1]. Between November 2002 and July 2003, an outbreak of SARS in southern China infected about 8000 people and led to 774 recorded deaths, mostly in Hong Kong [1]. Within weeks, SARS spread from Hong Kong to 37 countries [2]. A novel coronavirus (SARS-CoV) is responsible for SARS. The coronavirus responsible for Middle East Respiratory Syndrome (MERS-CoV) is similar to SARS-CoV. A better understanding of the features of SARS-CoV would help to guide control measures and treatment for similar diseases, such as MERS-CoV [3,4]. Lung injury caused by SARS-CoV is one of the main clinical manifestations and directly affects prognosis. Imaging plays an important role in the diagnosis and evaluation of patients with SARS. Thin-section computed tomography (CT) can show pulmonary abnormalities in patients with normal findings on plain X-ray and is useful in depicting the patterns and extent of the abnormalities [5-8]. During the acute phase of SARS, the more distinctive radiographic features include the predominant involvement of lung periphery and lower zone, and the absence of cavitation, hilar lymphadenopathy, and pleural effusion [9,10]. Radiographic progression from unilateral focal lesion to either multifocal or bilateral involvement during the second phase of the disease, followed by radiographic improvement with treatment, are commonly observed [9,10]. SARS is not only an acute disease, but also leads to long-term impaired lung diffusing capacity in about 24% of survivors [11], resulting in significantly lower exercise tolerance compared with the age-matched general population [11-13]. Another study suggested that the lung function impairment might not be related to the disease itself, but rather to extrapulmonary muscle weakness [14]. Nevertheless, 75% of SARS survivors still show lung abnormalities on thin-section CT 5 years after their illness onset [14]. However, there is a paucity of data regarding long-term CT findings in survivors after SARS. Therefore, the aim of the present study was to assess the changes in lung function and lung thin-section CT features in patients recovering from SARS, especially the dynamic changes in ground-glass opacity (GGO).

Material and Methods

Patients

Eleven patients who had been discharged after treatment for SARS as inpatients between February and June 2003 at Beijing Friendship Hospital were followed up at 3, 6, and 84 months using thin-section CT and were included in the present study. The diagnosis of SARS was based on the World Health Organization criteria [15]. This study received Ethics Committee approval from Beijing Friendship Hospital affiliated to Capital Medical University (Approval ID: 2015-P2-076-01). The committees waived the need for individual consent because of the retrospective nature of the study.

CT scans

The CT examinations were performed with an 8-row multidetector CT scanner (High Speed Ultra; GE Medical Systems, Milwaukee, WI, USA), and a 64-row multidetector CT scanner (LightSpeed Ultra; GE Medical Systems, Milwaukee, WI, USA) using the following parameters: 120 kVp, 150 mA, 5-mm collimation, 1.35:1 pitch, and reconstruction matrix of 512×512. The subjects were scanned in a supine position during breath-holding at full inspiration. Thin-section CT images were reconstructed with 0.625-mm or 1.25-mm collimation with a high spatial frequency algorithm or standard algorithm and then sent to the workstation (ADW 4.2; GE Medical Systems, Milwaukee, WI, USA) for analyzing. Thin-section CT images were evaluated using a lung window, with a window level of −600 HU and window width of 1500 HU. The soft-tissue window was not evaluated.

Image interpretation

All thin-section CT images were reviewed by 2 radiologists. The radiologists were aware of the diagnosis of SARS. For all scans, the radiologists were blinded to the names of the patients and the length of time since onset, but they were aware of which images belonged to the same patient. A consensus had to be reached between the 2 radiologists about the abnormalities. Discrepancies were solved by discussion. The radiologists determined the extent of the following thin-section CT abnormalities: ground-glass opacity, consolidation, reticular pattern, patchy decreased attenuation, and subpleural line, in accordance with the standard morphologic descriptors based on the Fleischner Society Nomenclature Committee recommendations [16] and other studies [17,18]. The evaluation of the extent of lung involvement was based on the segments of the lung anatomy: 10 segments in the right lung and 10 segments in the left lung (2 segments were considered in the apicoposterius segment left upper lobe and 2 segments were considered in the inferior front segment of the left lower lobe). The following rules were used to evaluate the lobe involvement: if more than half of the segment on the biggest scope of lesion level on axial thin-section CT was involved, then the segment (1 point) was recorded as being involved; if no more than half of the segment was involved, then 0.5 point was recorded. To evaluate the distribution of the lesion, it was also classified into 3 categories: 1) subpleural and/or peribronchovascular, 2) diffuse, or 3) irregular. In addition, each CT was divided into 3 categories: 1) anterior, 2) posterior, or 3) anterior and posterior. Finally, for every CT scan, the radiologists were required to generalize the main CT manifestation: 1) GGO predominant, or 2) fine reticulation predominant.

Pulmonary function test (PFT)

The PFT of the patients was classified into mild, moderate, or serious. We evaluated lung volumes (total lung capacity [TLC], vital capacity [VC], residual volume [RV], functional residual capacity [FRC] using the nitrogen washout method), spirometry (forced vital capacity [FVC], forced expiratory volume in 1 second [FEV1], FEV1/FVC ratio), and surface area for gas exchange (diffusion capacity adjusted for hemoglobin [DLCO]). The DLCO was determined using the single-breath carbon monoxide technique and an infrared analyzer. FEV1/expected% of <30%, 30–50%, 50–80%, and >80% were regarded as extremely serious, serious, moderate, and mild, respectively. DLCO values <80% of predicted were regarded as being impaired.

Statistical analysis

Descriptive statistics are presented. Continuous data are presented as means ± standard deviation (SD). Categorical data are presented as frequencies. SPSS 16.0 (IBM, Armonk, NY, USA) was used for statistical analysis.

Results

Characteristics of the patients

Eleven patients (8 females and 3 males; age range: 30–54 years, mean age: 38.6 years) met the selection criteria. Table 1 presents the demographic data and changes in lung function and lung radiographic features of the 11 patients during follow-up. All of the 11 patients were healthy before developing SARS and none were smokers. In acute phase, glucocorticoid was used in all 11 patients (methylprednisolone; the biggest dose was 840 mg/d, mean duration 9.5 days, and after improving for 2 or 3 days, methylprednisolone dose was decreased). All patients were still alive during the study period. Twenty-seven CT scans were evaluated. At 84 months, 5 patients were still experiencing persistent dyspnea, 4 had cough, 2 had sputum production, and 2 experienced all 3 symptoms. The mean time from discharge to the first follow-up was 3 months (range, 2 to 4 months).
Table 1

Characteristics of the patients.

Case numberGenderAge at onset3 months6 months84 months
Predominant HRCT findingsSegments involvedPredominant HRCT findingsSegments involvedPredominant HRCT findingsSegments involvedPFT
1F30GGO15Reticulation and interlobular thickening15Reticulation and interlobular thickening15Mild
2M35GGO3GGO2GGO1Mild
3M54Consolidation and GGO8GGO6Reticulation and interlobular thickening4N
4F38Diffuse GGO9GGO3Reticulation and interlobular thickening3Mild
5F42Consolidation and GGO13Reticulation and interlobular thickening7Reticulation and interlobular thickening5Mild
6F32GGO14Reticulation and interlobular thickening11.5Mild
7M31GGO18Reticulation and interlobular thickening9.5Mild
8F31Reticulation and interlobular thickening5Reticulation and interlobular thickening3.5Mild
9F40GGO9Reticulation and interlobular thickening6.5Moderate
10F48GGO18GGO16Mild
11F36GGO9Normal0N

Thin-section CT findings

Table 2 presents the thin-section CT findings. All 11 patients underwent CT scans at 6- and 84-month follow-up. Multiple lobes or segments were involved in all 11 cases. Among them, 48 segments (average of 10 segments per patient) were involved at 3 months, 106 segments (average of 9.6 per case) were involved at 6 months, and 75 segments (average of 6.8 per case) were involved at 84 months. At 3 months, as the predominant thin-section CT feature, 2 patients (40.0%) showed GGO (Figure 1) and 3 showed consolidation and GGO (60.0%) (Figure 2). At 6 months, as the predominant thin-section CT feature, 3 patients (27.3%) showed reticulation and interlobular thickening (Figure 3) and 8 (72.7%) showed GGO. At 84 months, as the predominant thin-section CT feature, 1 patient (9.1%) had no lung abnormality, 8 patients (72.7%) showed reticulation and interlobular thickening, and 2 (18.2%) showed GGO. Traction bronchiectasis was found in 3 patients (Figure 3), while patchy decreased attenuation was found in 1 patient (Figure 1). Traction bronchiectasis was found at 6- and 84-month thin-section CT, and patchy decreased attenuation was found at 3-, 6-, and 84-month thin-section CT.
Table 2

CT findings during follow-up.

CT findings3 months (n=5)6 months (n=11)84 months (n=11)
GGO5 (100.0%)11 (100.0%)10 (90.9%)
Consolidation5 (100.0%)00
Reticulation5 (100.0%)9 (81.7%)10 (90.9%)
Subpleural line1 (20.0%)1 (9.1%)1 (9.1%)
Traction brochiectasis02 (18.2%)2 (18.2%)
Air trapping1 (20.0%)1 (9.1%)1 (9.1%)
Small nodule2 (40.0%)2 (18.2%)2 (9.1%)
GGO predominance5 (100.0%)2 (18.2%)
Reticulation predominance03 (27.3%)8 (72.7%)
Distribution of peripheral3 (60.0%)9 (81.7%)9 (81.7%)
Distribution on axial section (anterior and posterior)5 (100.0%)11 (100.0%)10 (90.9%)
Segments involved48 (48/500)106 (106/2200)75 (75/2200)
Figure 1

Case 1, SARS survivor, female, 30 years old. (A) The CT scan at 3 months showed diffuse bilateral GGO (arrow). (B) Six months later, GGO was reduced. (C) At 84 months, GGO was greatly reduced and fine reticulation (intralobular and interlobular septal thickening) predominated (arrow). Patchy decreased attenuation was seen at 3-, 6-, and 84-month CT (triangle).

Figure 2

Case 7, SARS survivor, male, 31 years old. (A) Chest radiography showed consolidation in the lower lobes of both lungs in acute phase. (B) Six months later, GGO (triangle) and reticulation (arrow) were observed in both lungs. (C) Fine reticulation (arrow) still persisted but GGO could not be found at 84-month CT.

Figure 3

Case 6, SARS survivor, female, 32 years old. (A) X-ray radiography showed a large consolidation in the lower lobes of both lungs in acute phase. (B) Six months later, X-ray revealed GGO, septal thickening, and fine-mesh shadows (white arrow). Traction bronchiectasis was found in the left lower lobe. (C) At 84 months, GGO was reduced and interlobular thickening predominated. Traction bronchiectasis was still present.

Pulmonary function test

The PFT results of the 11 patients at 84 months are presented in Table 1. Two patients (18%) had a normal PFT. Nine patients (81.8%) had a low DLCO. Eight patients (72.7%) had mild lung function damage, and 1 (9.1%) had moderate lung function damage.

Trends in changes in predominant thin-section CT findings over time

Table 2 shows that the predominant CT findings in SARS survivors shift from a predominance of the GGO feature at 3 (100.0%) and 6 (72.7%) months to the predominance of reticulation and interlobular thickening at 84 months (72.7%). Figuress 1–3 present typical thin-section CT imaging at 3, 6, and 84 months, respectively.

Discussion

During viral lung infections, the lungs histologically show diffuse alveolar damage, including interstitial lymphocyte infiltration, air-space hemorrhage, edema, fibrosis, type 2 cell hyperplasia, and hyaline tissue formation [19]. Diffuse alveolar damage is found in some kinds of viral pneumonia, but it is usually self-limited and radiologic abnormalities usually diminish within 3 weeks in immunocompetent patients [20]. In SARS-CoV-infected patients, intralobular and interlobular septal thickening, subpleural lines, and traction bronchiectasis were observed as late as 84 months after SARS infection in the present study. All these thin-section CT manifestations were also found at 3 and 6 months during the recovery phase of SARS, which may indicate lung fibrosis, as observed in previous studies [21,22]. To the best of our knowledge, the present study is the first to report abnormal imaging at up to 7 years after SARS-CoV pneumonia. The characteristic thin-section CT finding in SARS survivors changed from GGO predominance at 3–6 months to fine reticulation (intralobular and interlobular septal thickening) predominance at 7 years. GGO was found in 8 patients at 6 months and in 2 patients at 84 months. Some studies reported the imaging features of the recovery phase in patients with SARS [21,22]. Antonio et al. [21] analyzed the thin-section CT findings at an average of 36.5 days in 24 patients and observed that the main findings in the recovery phase were GGO, intralobular and interlobular septal thickening, traction bronchiectasis, and subpleural lines. They also reported that fibrosis began early and tended to be found in elderly and more seriously affected patients. However, in the present study, all 11 patients showed abnormalities that may indicate fibrosis at 6 months, and 10 patients still had signs of lung fibrosis after 7 years. All patients were 30–54 years old when they were infected by SARS-CoV; therefore, lung fibrosis could be a long-term sequela of SARS-CoV infection. Importantly, the thin-section CT lung abnormalities observed in the present study seemed to be different from those induced by other pneumonia viruses [23,24]. It is known that many SARS patients suffer from ARDS/DAD in the acute phase [25]. Nevertheless, the present study suggests that either the lung fibrosis is very slow to disappear after infection or that the CT abnormality is different from lung fibrosis induced by other pneumonia viruses. However, the results of the present study do not resolve this issue. With regard to the physical impairment that may accompany the abnormalities on thin-section CT, some previous studies suggest that the physical impairment after SARS persists for at least 12 months [11,13], while another study suggests only mild impairments at 5 years [14]. A study has shown that the immune response after SARS persists for at least 90 days [26], but no data is available to determine exactly how long it persists and whether it could involve lungs as a long-term sequela. In our study, mild or moderate pulmonary function damage was still present in 81.8% of the patients at 7 years after SARS infection. Some studies have shown that after the acute phase of ARDS, CT findings are variable [26-28]. In ARDS, although complete resolution of abnormalities may occur, the typical CT findings at the later stage are that of a coarse reticular pattern and GGO in the anterior part of the lungs [25,27,29]. In this setting, it is likely that GGO represents areas of fine fibrosis, which are observed on thin-section CT. Our study shows that the CT abnormalities of all patients had a diffuse distribution, which was similar that reported in a recent study by Masclans et al. [30]. Indeed, Masclans et al. [30] found that 76% of patients had abnormalities on high-resolution CT at 6 months after infection, and these abnormalities were typically areas of reticulation and GGO. Therefore, the distribution of thin-section abnormalities in our study seem to be different from those reported in some other studies [25,27,29] on late-stage ARDS. However, drawing conclusions is impossible because of the lack of accompanying histopathological examination in most patients with SARS and ARDS. Another finding of the present study is the presence of traction bronchiectasis, which represents airway abnormalities, as well as patchy decreased attenuation, which probably represents airway abnormalities. Traction bronchiectasis was found in 3 patients, while patchy decreased attenuation was found in 1 patient. Similar results in SARS patients were also reported in some other studies [24,31]. Masclans et al. [30] found that airway disease was more common in ARDS survivors, again suggesting the possibility of the presence of underlying lung fibrosis in these survivors of SARS. The present study is not without limitations. This was a retrospective review of patients evaluated at 2 centers, with all of the issues of selection and observational biases that this design entails. Secondly, the sample size was smaller than that of prior studies and may not represent most patients. Thirdly, the pulmonary function test results at 3 and 6 months were unavailable in most patients.

Conclusions

This study of 11 SARS patients found that lung abnormalities on thin-section CT still existed in SARS survivors 7 years after infection, though the extent became less. During convalescence after SARS, GGO and intralobular and interlobular septal thickening were the main thin-section CT manifestations. From 6 months to 7 years after SARS, the predominant thin-section CT findings changed from GGO predominance to fine reticulation predominance, which probably represents the interstitial fibrotic proliferation recovery phase of diffuse alveolar damage. These abnormalities were consistent with the PFT.
  27 in total

Review 1.  Pulmonary complications of solid organ and hematopoietic stem cell transplantation.

Authors:  Robert M Kotloff; Vivek N Ahya; Stephen W Crawford
Journal:  Am J Respir Crit Care Med       Date:  2004-04-07       Impact factor: 21.405

2.  Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors.

Authors:  C K Ng; J W M Chan; T L Kwan; T S To; Y H Chan; F Y Y Ng; T Y W Mok
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

3.  Long-term sequelae of SARS: physical, neuropsychiatric, and quality-of-life assessment.

Authors:  D S C Hui; K T Wong; G E Antonio; M Tong; D P Chan; J J Y Sung
Journal:  Hong Kong Med J       Date:  2009-12       Impact factor: 2.227

Review 4.  Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease.

Authors:  Loren Ketai; Narinder S Paul; Ka-tak T Wong
Journal:  J Thorac Imaging       Date:  2006-11       Impact factor: 3.000

5.  Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society.

Authors:  J H Austin; N L Müller; P J Friedman; D M Hansell; D P Naidich; M Remy-Jardin; W R Webb; E A Zerhouni
Journal:  Radiology       Date:  1996-08       Impact factor: 11.105

6.  Severe acute respiratory syndrome: 11 years later--a radiology perspective.

Authors:  Apoorva Gogna; Kiang Hiong Tay; Bien Soo Tan
Journal:  AJR Am J Roentgenol       Date:  2014-10       Impact factor: 3.959

Review 7.  Viral pneumonias in adults: radiologic and pathologic findings.

Authors:  Eun A Kim; Kyung Soo Lee; Steven L Primack; Hye Kyung Yoon; Hong Sik Byun; Tae Sung Kim; Gee Young Suh; O Jung Kwon; Joungho Han
Journal:  Radiographics       Date:  2002-10       Impact factor: 5.333

Review 8.  Pulmonary complications following bone marrow transplantation.

Authors:  T M Wah; H A Moss; R J H Robertson; D L Barnard
Journal:  Br J Radiol       Date:  2003-06       Impact factor: 3.039

Review 9.  Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.

Authors:  David S Hui; Ziad A Memish; Alimuddin Zumla
Journal:  Curr Opin Pulm Med       Date:  2014-05       Impact factor: 3.155

10.  Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS.

Authors:  Chun-Hua Wang; Chien-Ying Liu; Yung-Liang Wan; Chun-Liang Chou; Kuo-Hsiung Huang; Horng-Chyuan Lin; Shu-Min Lin; Tzou-Yien Lin; Kian Fan Chung; Han-Pin Kuo
Journal:  Respir Res       Date:  2005-05-11
View more
  42 in total

1.  Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Thiagarajan Venkataraman; Christopher M Coleman; Matthew B Frieman
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

2.  Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways.

Authors:  Daniel Aguilar; Adelaida Bosacoma; Isabel Blanco; Olga Tura-Ceide; Anna Serrano-Mollar; Joan Albert Barberà; Victor Ivo Peinado
Journal:  Life (Basel)       Date:  2022-06-14

3.  Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19.

Authors:  Antonio Vitiello; Francesco Ferrara
Journal:  Lung India       Date:  2021-03

Review 4.  The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis.

Authors:  Thiagarajan Venkataraman; Matthew B Frieman
Journal:  Antiviral Res       Date:  2017-04-05       Impact factor: 5.970

5.  The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study.

Authors:  Dehan Liu; Wanshu Zhang; Feng Pan; Lin Li; Lian Yang; Dandan Zheng; Jiazheng Wang; Bo Liang
Journal:  Respir Res       Date:  2020-05-24

6.  Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.

Authors:  Peixun Zhang; Jia Li; Huixin Liu; Na Han; Jiabao Ju; Yuhui Kou; Lei Chen; Mengxi Jiang; Feng Pan; Yali Zheng; Zhancheng Gao; Baoguo Jiang
Journal:  Bone Res       Date:  2020-02-14       Impact factor: 13.567

7.  Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?

Authors:  Elia Bari; Ilaria Ferrarotti; Laura Saracino; Sara Perteghella; Maria Luisa Torre; Luca Richeldi; Angelo Guido Corsico
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

Review 8.  Changes in the respiratory function of COVID-19 survivors during follow-up: A novel respiratory disorder on the rise?

Authors:  Afroditi K Boutou; Athina Georgopoulou; Georgia Pitsiou; Ioannis Stanopoulos; Theodoros Kontakiotis; Ioannis Kioumis
Journal:  Int J Clin Pract       Date:  2021-05-17       Impact factor: 3.149

9.  Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome.

Authors:  Wan Beom Park; Kang Il Jun; Gayeon Kim; Jae-Phil Choi; Ji-Young Rhee; Shinhyea Cheon; Chang Hyun Lee; Jun-Sun Park; Yeonjae Kim; Joon-Sung Joh; Bum Sik Chin; Pyeong Gyun Choe; Ji Hwan Bang; Sang-Won Park; Nam Joong Kim; Dong-Gyun Lim; Yeon-Sook Kim; Myoung-Don Oh; Hyoung-Shik Shin
Journal:  J Korean Med Sci       Date:  2018-05-10       Impact factor: 2.153

Review 10.  Imaging of Emerging Infectious Diseases.

Authors:  Meghan Jardon; Shaden F Mohammad; Cecilia M Jude; Anokh Pahwa
Journal:  Curr Radiol Rep       Date:  2019-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.